Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

NCT02566993 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

613

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: Lurbinectedin (PM01183)
DRUG: Doxorubicin (DOX)
DRUG: Cyclophosphamide (CTX)
DRUG: Vincristine (VCR)
DRUG: Topotecan

Sponsor

PharmaMar